Friday, November 11, 2011

Vaccine Getting Ready to Contest Breast Cancer, Ovarian Cancer ...

In what may well turn out to be dream come true for patients suffering from the detrimental breast cancer and ovarian cancer, it has recently been revealed that monthly shots of a vaccine to contest cancer has showed off heartening results in an initial, small but effective trial of 26 women suffering from stern ovarian cancer and metastatic breast, the majority of whom had already gone through three or more sessions of chemotherapy.

The said form of cancer is highly grave-inspiring as it has a tendency of expanding its presence to various other parts around the body of the patient. Amid the 12 patients enduring breast cancer, experts revealed that median time of survival was 13.7 months, though one patient was alive even after 37 months, at the when the reports were being compiled. On the other hand, four patients were reported having a secure condition at the time of the trial.

For the remaining 14 patients suffering from ovarian cancer, the median rate of survival was 15 months, though doctors revealed that one woman even saw the 38th month ahead of a progression in her disease.

The reports made it clear that the side effects of the said therapy were mostly gentle, as by and large the patients witnessed mild reactions on at the injection site, while one patient apparently caught anemia.

Though the reports, which have been made available in the journal Clinical Cancer Research, are more or less encouraging, the fact has been admitted by the researchers that it?s just an initial observation made through the execution of an early pilot trial. They admitted that these findings cannot be regarded as final and decisive, as they neither had a control group nor they discussed how long patients is likely to survive without such treatment.

Source: http://topnews.us/content/244658-vaccine-getting-ready-contest-breast-cancer-ovarian-cancer

apple earnings tampa weather pat buchanan susan sarandon susan sarandon motorola razr camille grammer

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.